Joanne E Mortimer1, James R Bading2, Paul H Frankel3, Mary I Carroll2, Yuan Yuan2, Jinha M Park4, Lusine Tumyan4, Nikita Gidwaney4, Erasmus K Poku5, John E Shively5, David M Colcher5. 1. Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California; jmortimer@coh.org. 2. Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California. 3. Department of Information Sciences, City of Hope, Duarte, California. 4. Department of Radiology, City of Hope, Duarte, California; and. 5. Department of Cancer Molecular Imaging and Therapy, Beckman Research Institute of the City of Hope, Duarte, California.
Abstract
We hypothesized that functional imaging with 64Cu-DOTA-trastuzumab PET/CT would predict the response to the antibody-drug conjugate trastuzumab-emtansine (T-DM1). Methods: Ten women with metastatic human epidermal growth factor receptor 2-positive breast cancer underwent 18F-FDG PET/CT and 64Cu-DOTA-trastuzumab PET/CT on days 1 and 2 before treatment with T-DM1. Results: T-DM1-responsive patients had higher uptake than nonresponsive patients. Day 1 minimum SUVmax (5.6 vs. 2.8, P < 0.02), day 2 minimum SUVmax (8.1 vs. 3.2, P < 0.01), and day 2 average SUVmax (8.5 vs. 5.4, P < 0.05) for 64Cu-DOTA-trastuzumab all favored responding patients. Tumor-level response suggested threshold dependence on SUVmax Patients with a day 2 minimum SUVmax above versus below the threshold had a median time to treatment failure of 28 mo versus 2 mo (P < 0.02). Conclusion: Measurement of trastuzumab uptake in tumors via PET/CT is promising for identifying patients with metastatic breast cancer who will benefit from T-DM1.
We hypothesized that functional imaging with 64Cu-DOTA-trastuzumab PET/CT would predict the response to the antibody-drug conjugate trastuzumab-emtansine (T-DM1). Methods: Ten women with metastatic human epidermal growth factor receptor 2-positive breast cancer underwent 18F-FDG PET/CT and 64Cu-DOTA-trastuzumab PET/CT on days 1 and 2 before treatment with T-DM1. Results: T-DM1-responsive patients had higher uptake than nonresponsive patients. Day 1 minimum SUVmax (5.6 vs. 2.8, P < 0.02), day 2 minimum SUVmax (8.1 vs. 3.2, P < 0.01), and day 2 average SUVmax (8.5 vs. 5.4, P < 0.05) for 64Cu-DOTA-trastuzumab all favored responding patients. Tumor-level response suggested threshold dependence on SUVmax Patients with a day 2 minimum SUVmax above versus below the threshold had a median time to treatment failure of 28 mo versus 2 mo (P < 0.02). Conclusion: Measurement of trastuzumab uptake in tumors via PET/CT is promising for identifying patients with metastatic breast cancer who will benefit from T-DM1.
Authors: Joanne E Mortimer; James R Bading; Jinha M Park; Paul H Frankel; Mary I Carroll; Tri T Tran; Erasmus K Poku; Russell C Rockne; Andrew A Raubitschek; John E Shively; David M Colcher Journal: J Nucl Med Date: 2017-06-21 Impact factor: 10.057
Authors: Joanne E Mortimer; James R Bading; David M Colcher; Peter S Conti; Paul H Frankel; Mary I Carroll; Shan Tong; Erasmus Poku; Joshua K Miles; John E Shively; Andrew A Raubitschek Journal: J Nucl Med Date: 2013-12-12 Impact factor: 10.057
Authors: Gary A Ulaner; David M Hyman; Dara S Ross; Adriana Corben; Sarat Chandarlapaty; Shari Goldfarb; Heather McArthur; Joseph P Erinjeri; Stephen B Solomon; Hartmuth Kolb; Serge K Lyashchenko; Jason S Lewis; Jorge A Carrasquillo Journal: J Nucl Med Date: 2016-05-05 Impact factor: 10.057
Authors: Richard Laforest; Suzanne E Lapi; Reiko Oyama; Ron Bose; Adel Tabchy; Bernadette V Marquez-Nostra; Jennifer Burkemper; Brian D Wright; Jennifer Frye; Sarah Frye; Barry A Siegel; Farrokh Dehdashti Journal: Mol Imaging Biol Date: 2016-12 Impact factor: 3.488
Authors: Sharon H Giordano; Sarah Temin; Sarat Chandarlapaty; Jennie R Crews; Francisco J Esteva; Jeffrey J Kirshner; Ian E Krop; Jennifer Levinson; Nancy U Lin; Shanu Modi; Debra A Patt; Jane Perlmutter; Naren Ramakrishna; Eric P Winer; Nancy E Davidson Journal: J Clin Oncol Date: 2018-06-25 Impact factor: 44.544
Authors: Antonio C Wolff; M Elizabeth Hale Hammond; Kimberly H Allison; Brittany E Harvey; Pamela B Mangu; John M S Bartlett; Michael Bilous; Ian O Ellis; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Lisa M McShane; Mitchell Dowsett Journal: J Clin Oncol Date: 2018-05-30 Impact factor: 44.544
Authors: G Gebhart; L E Lamberts; Z Wimana; C Garcia; P Emonts; L Ameye; S Stroobants; M Huizing; P Aftimos; J Tol; W J G Oyen; D J Vugts; O S Hoekstra; C P Schröder; C W Menke-van der Houven van Oordt; T Guiot; A H Brouwers; A Awada; E G E de Vries; P Flamen Journal: Ann Oncol Date: 2015-11-23 Impact factor: 32.976